MiR-155-5p promotes renal interstitial fibrosis in obstructive nephropathy via inhibiting SIRT1 signaling pathway

References

• Stevens S. Obstructive Kidney Disease. Nurs Clin North Am. 2018;53(4):569–578.
   PubMed Web of Science ®Google Scholar
• Wilson DR. Pathophysiology of obstructive nephropathy. Kidney Int. 1980;18(3):281–292.
   PubMed Web of Science ®Google Scholar
• Klahr S, Purkerson ML. The pathophysiology of obstructive nephropathy: the role of vasoactive compounds in the hemodynamic and structural abnormalities of the obstructed kidney. Am J Kidney Dis. 1994;23(2):219–223.
   PubMed Web of Science ®Google Scholar
• Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol. 2002;283(5):F861–F875.
   PubMed Web of Science ®Google Scholar
• Becker GJ, Hewitson TD. The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens. 2000;9(2):133–138.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.
   PubMed Web of Science ®Google Scholar
• Cruz-Solbes AS, Youker K. Epithelial to Mesenchymal Transition (EMT) and Endothelial to Mesenchymal Transition (EndMT): role and implications in kidney fibrosis. Results Probl Cell Differ. 2017;60:345–372.
   PubMedGoogle Scholar
• Lovisa S, LeBleu VS, Tampe B, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 2015;21(9):998–1009.
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–1207.
   PubMed Web of Science ®Google Scholar
• Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35(1):3–11.
   PubMed Web of Science ®Google Scholar
• Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, et al. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465.
   PubMed Web of Science ®Google Scholar
• Wang L, Song G, Tan W, et al. MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition. Oncotarget. 2015;6(34):35978–35990.
   PubMedGoogle Scholar
• Ma M, He M, Jiang Q, et al. MiR-487a promotes TGF-β1-induced EMT, the migration and invasion of breast cancer cells by directly targeting MAGI2. Int J Biol Sci. 2016;12(4):397–408.
   PubMed Web of Science ®Google Scholar
• Suzuki HI, Katsura A, Mihira H, et al. Regulation of TGF-β-mediated endothelial-mesenchymal transition by microRNA-27. J Biochem. 2017;161(5):417–420.
   PubMed Web of Science ®Google Scholar
• Ding L, Zhang Z, Shang D, et al. α-Smooth muscle actin-positive myofibroblasts, in association with epithelial-mesenchymal transition and lymphogenesis, is a critical prognostic parameter in patients with oral tongue squamous cell carcinoma. J Oral Pathol Med. 2014;43(5):335–343.
   PubMed Web of Science ®Google Scholar
• Kim KK, Sheppard D, Chapman HA. TGF-β1 signaling and tissue fibrosis. Cold Spring Harb Perspect Biol. 2018;10(4):a022293.
   PubMed Web of Science ®Google Scholar
• Li T, Yan Y, Wang B, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22(6):845–854.
   PubMed Web of Science ®Google Scholar
• Xie S, Chen H, Li F, et al. Hypoxia-induced microRNA-155 promotes fibrosis in proximal tubule cells. Mol Med Rep. 2015;11(6):4555–4560.
   PubMed Web of Science ®Google Scholar
• Lin XQ, Huang ZM, Chen X, et al. XIST induced by JPX suppresses hepatocellular carcinoma by sponging miR-155-5p. Yonsei Med J. 2018;59(7):816–826.
   PubMed Web of Science ®Google Scholar
• Chen L, Zheng SY, Yang CQ, et al. MiR-155-5p inhibits the proliferation and migration of VSMCs and HUVECs in atherosclerosis by targeting AKT1. Eur Rev Med Pharmacol Sci. 2019;23(5):2223–2233.
   PubMed Web of Science ®Google Scholar
• Liu S, Zou H, Wang Y, et al. miR-155-5p is negatively associated with acute pancreatitis and inversely regulates pancreatic acinar cell progression by targeting rela and Traf3. Cell Physiol Biochem. 2018;51(4):1584–1599.
   PubMedGoogle Scholar
• Zhou X, Yan T, Huang C, et al. Melanoma cell-secreted exosomal miR-155-5p induce proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway. J Exp Clin Cancer Res. 2018;37(1):242.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng ZJ, Jia YJ, et al. Role of p53/miR-155-5p/sirt1 loop in renal tubular injury of diabetic kidney disease. J Transl Med. 2018;16(1):146.
   PubMedGoogle Scholar
• Pang M, Kothapally J, Mao H, et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol. 2009;297(4):F996–F1005.
   PubMed Web of Science ®Google Scholar
• Ren Y, Du C, Shi Y, et al. The Sirt1 activator, SRT1720, attenuates renal fibrosis by inhibiting CTGF and oxidative stress. Int J Mol Med. 2017;39(5):1317–1324.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu D, Yao J, et al. Inhibition of miR-155-5p exerts anti-fibrotic effects in silicotic mice by regulating Meprin α. Mol Ther Nucleic Acids. 2020;19:350–360.
   PubMedGoogle Scholar
• Alves-Fernandes DK, Jasiulionis MG. The role of SIRT1 on DNA damage response and epigenetic alterations in cancer. Int J Mol Sci. 2019;20(13):3153.
   PubMed Web of Science ®Google Scholar
• Li M, Hong W, Hao C, et al. SIRT1 antagonizes liver fibrosis by blocking hepatic stellate cell activation in mice. Faseb J. 2018;32(1):500–511.
   PubMed Web of Science ®Google Scholar
• Tang BL. Sirt1 and the mitochondria. Mol Cells. 2016;39(2):87–95.
   PubMed Web of Science ®Google Scholar
• Ponnusamy M, Zhou X, Yan Y, et al. Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy. J Pharmacol Exp Ther. 2014;350(2):243–256.
   PubMed Web of Science ®Google Scholar
• Han W, Wang C, Yang Z, et al. SRT1720 retards renal fibrosis via inhibition of HIF1α/GLUT1 in diabetic nephropathy. J Endocrinol. 2019;241(1):85–98.
   Web of Science ®Google Scholar